Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.30 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Serine SCHEMBL5320795 | 0.86 | SLC7A5 (0.39) | SLC7A5SLC1A1SLC1A3SLC1A2USP2 | |
| Serine SCHEMBL6666261 | 0.86 | SLC7A5 (0.38) | SLC7A5SLC1A1SLC1A3SLC1A2GRIK1 | |
| Serine SCHEMBL1067385 | 0.84 | SLC7A5 (0.37) | SLC7A5PDCD1LG2CD274SLC1A1SLC1A3 | |
| Threonine SCHEMBL2765872 | 0.84 | SLC7A5 (0.39) | SLC7A5SLC1A1SLC1A3SLC1A2USP2 | |
| SCHEMBL442281 | 0.84 | SLC7A5 (0.30) | SLC7A5 | |
| Leucine SCHEMBL15323191 | 0.82 | SLC7A5 (0.53) | SLC7A5SLC1A1SLC1A3SLC1A2GRIK1 | |
| Threonine SCHEMBL6856748 | 0.81 | SLC7A5 (0.36) | SLC7A5SLC1A1SLC1A3SLC1A2USP2 | |
| Threonine SCHEMBL5698237 | 0.80 | USP2 (0.39) | SLC7A5PDCD1LG2CD274SLC1A1SLC1A3 | |
| Threonine SCHEMBL1031790 | 0.80 | USP2 (0.39) | SLC7A5PDCD1LG2CD274SLC1A1SLC1A3 | |
| Threonine SCHEMBL5073183 | 0.80 | SLC7A5 (0.38) | SLC7A5SLC1A1SLC1A3SLC1A2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4178612-A1 | SARS-COV-2 AND INFLUENZA COMBINATION VACCINE | Spicona Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| WO-2022009121-A1 | SARS-COV-2 AND INFLUENZA COMBINATION VACCINE | SPICONA INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| EP-1185631-B1 | NOVEL ENDO-BETA-1,4-GLUCANASES | NOVOZYMES AS (DK) | 2006-08-09 | — | — | EP | disclosed |
| EP-1185631-A1 | NOVEL ENDO-BETA-1,4-GLUCANASES | Novozymes A/S (DK) | 2002-03-13 | — | — | EP | disclosed |
| WO-2001059083-A1 | BACTERIAL GALACTANASES AND USE THEREOF | NOVOZYMES A/S (DK) | 2001-08-16 | — | — | WO | disclosed |
| US-6165769-A | Pectin degrading enzymes from Bacillus licheniformis | NOVO NORDISK A/S (DK) | 2000-12-26 | — | — | US | disclosed |
| WO-2000073428-A1 | NOVEL ENDO-BETA-1,4-GLUCANASES | NOVOZYMES A/S (DK) | 2000-12-07 | — | — | WO | disclosed |
| US-6153420-A | PROTEIN WITH ENZYMATIC ACTIVITY; FOR THE DETECTION OF MODULATORS OR ENZYMATIC ACTIVITY; FOR CLEAVING PEPTIDE LINKAGE OF SUBSTRATE PROTEIN; FOR USE AS DIAGNOSTIC TOOLS IN GENETIC ENGINEERING | ZYMOGENETICS, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| US-6143874-A | FOR STIMULATING B-CELL AND/OR T CELL PRODUCTION; ANTIINFLAMMATORY AGENTS; TREATMENT OF ALZHEIMER'S/PARKINSON'S DISEASES, AMYOTROPHIC LATERAL SCLEROSIS, AND VARIOUS DEGENERATIVE DISORDERS THAT AFFECT VISION | AMGEN INC (US) | 2000-11-07 | — | — | US | disclosed |
| US-6143720-A | FOR DETECTING GENETIC ABNORMALITY IN MAMMALS | ZYMOGENETICS, INC. (US) | 2000-11-07 | — | — | US | disclosed |
| US-5925735-A | POLYPEPTIDE | ZYMOGENETICS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5919656-A | NUCLEIC ACID MOLECULES; ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS, ANTIPROLIFERATIVE AGENTS, GENE THERAPY; AGE RESISTANCE | AMGEN CANADA INC. (CA) | 1999-07-06 | — | — | US | disclosed |
| US-5914251-A | GENE FOR A POLYPEPTIDE WHICH ACTIVATES PROPAGATION OF PROSTATE AND EPITHELIAL TISSUES; DIAGNOSIS; ANTICARCINOGENIC/ANTITUMOR AGENTS | AMGEN INC. (US) | 1999-06-22 | — | — | US | disclosed |
| WO-1999002663-A1 | ALKALINE XYLOGLUCANASE | NOVO NORDISK A/S (DK) | 1999-01-21 | — | — | WO | disclosed |
| US-5859197-A | ISOLATED NEURITIN POLYPEPTIDE WHICH PROMOTES NEURITOGENESIS IN HIPPOCAMPAL OR CORTICAL NEURONAL CULTURES | AMGEN INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5817784-A | POLYPEPTIDE TERMINED NEURITIN WHICH IS EXPRESSED PRIMARY IN BRAIN TISSUE | AMGEN INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5792850-A | ISOLATED POLYNUCLEOTIDE ENCODING A POLYPEPTIDE AS A STIMULANT LIGAND-BINDING RECEPTOR | ZYMOGENETICS, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5766877-A | GENE EXPRESSION | AMGEN INC. (US) | 1998-06-16 | — | — | US | disclosed |
| US-5741772-A | POLYPEPTIDE | AMGEN INC. (US) | 1998-04-21 | — | — | US | disclosed |
| US-5641655-A | GENETIC ENGINEERED DNA ENCODING A PROTEIN FUSION | ZYMOGENETICS, INC. (US) | 1997-06-24 | — | — | US | disclosed |